{"id":32147,"date":"2025-04-21T16:26:37","date_gmt":"2025-04-21T08:26:37","guid":{"rendered":"https:\/\/flcube.com\/?p=32147"},"modified":"2025-04-21T16:26:38","modified_gmt":"2025-04-21T08:26:38","slug":"belief-biomed-gains-nmpa-clinical-trial-approval-for-dmd-gene-therapy-bbm-d101","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32147","title":{"rendered":"Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101"},"content":{"rendered":"\n

China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its BBM-D101 gene therapy for Duchenne muscular dystrophy (DMD). This follows clinical clearance from the US regulatory authorities in January this year, marking a significant step forward in the development of this innovative treatment.<\/p>\n\n\n\n

BBM-D101: Mechanism and Innovation<\/strong>
BBM-D101 is an in-house developed recombinant adeno-associated virus (rAAV) gene therapy. It uses an engineered AAV vector to deliver optimized gene expression cassettes to muscles throughout the body. This approach aims to effectively treat DMD by addressing the root cause of the disease through targeted gene delivery and expression.<\/p>\n\n\n\n

Clinical Trial and Future Outlook<\/strong>
With clinical trial approval secured, Belief BioMed is poised to initiate studies to evaluate the safety and efficacy of BBM-D101 in patients with DMD. This development highlights the company\u2019s commitment to advancing gene therapy solutions for patients with severe genetic disorders.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical…<\/p>\n","protected":false},"author":1,"featured_media":32148,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[465,62,66,24],"class_list":["post-32147","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-belief-biomed","tag-clinical-trial-approval-initiation","tag-gene-therapy","tag-rare-orphan-disease-drugs"],"yoast_head":"\nBelief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its BBM-D101 gene therapy for Duchenne muscular dystrophy (DMD). This follows clinical clearance from the US regulatory authorities in January this year, marking a significant step forward in the development of this innovative treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32147\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101\" \/>\n<meta property=\"og:description\" content=\"China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its BBM-D101 gene therapy for Duchenne muscular dystrophy (DMD). This follows clinical clearance from the US regulatory authorities in January this year, marking a significant step forward in the development of this innovative treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32147\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-21T08:26:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-21T08:26:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2115.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32147#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32147\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101\",\"datePublished\":\"2025-04-21T08:26:37+00:00\",\"dateModified\":\"2025-04-21T08:26:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32147\"},\"wordCount\":175,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32147#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2115.webp\",\"keywords\":[\"Belief BioMed\",\"Clinical trial approval \\\/ initiation\",\"Gene therapy\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32147#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32147\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32147\",\"name\":\"Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32147#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32147#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2115.webp\",\"datePublished\":\"2025-04-21T08:26:37+00:00\",\"dateModified\":\"2025-04-21T08:26:38+00:00\",\"description\":\"China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its BBM-D101 gene therapy for Duchenne muscular dystrophy (DMD). This follows clinical clearance from the US regulatory authorities in January this year, marking a significant step forward in the development of this innovative treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32147#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32147\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32147#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2115.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2115.webp\",\"width\":1080,\"height\":608,\"caption\":\"Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32147#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101 - Insight, China's Pharmaceutical Industry","description":"China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its BBM-D101 gene therapy for Duchenne muscular dystrophy (DMD). This follows clinical clearance from the US regulatory authorities in January this year, marking a significant step forward in the development of this innovative treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32147","og_locale":"en_US","og_type":"article","og_title":"Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101","og_description":"China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its BBM-D101 gene therapy for Duchenne muscular dystrophy (DMD). This follows clinical clearance from the US regulatory authorities in January this year, marking a significant step forward in the development of this innovative treatment.","og_url":"https:\/\/flcube.com\/?p=32147","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-21T08:26:37+00:00","article_modified_time":"2025-04-21T08:26:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2115.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32147#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32147"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101","datePublished":"2025-04-21T08:26:37+00:00","dateModified":"2025-04-21T08:26:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32147"},"wordCount":175,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32147#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2115.webp","keywords":["Belief BioMed","Clinical trial approval \/ initiation","Gene therapy","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32147#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32147","url":"https:\/\/flcube.com\/?p=32147","name":"Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32147#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32147#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2115.webp","datePublished":"2025-04-21T08:26:37+00:00","dateModified":"2025-04-21T08:26:38+00:00","description":"China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its BBM-D101 gene therapy for Duchenne muscular dystrophy (DMD). This follows clinical clearance from the US regulatory authorities in January this year, marking a significant step forward in the development of this innovative treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32147#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32147"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32147#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2115.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2115.webp","width":1080,"height":608,"caption":"Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32147#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2115.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32147"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32147\/revisions"}],"predecessor-version":[{"id":32149,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32147\/revisions\/32149"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32148"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32147"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32147"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}